German science and technology major Merck KgaA reported Thursday higher profit and revenues in its fiscal 2022, with improved performance in all divisions. The company further lifted its dividend, and said it expects weak to flat EBITDA pre in fiscal 2023, but higher organic sales.
Belen Garijo, Chair of the Executive Board and CEO of Merck, said, "We delivered profitable growth in fiscal 2022 despite challenges. The strong development of the Life Science core business more than offset the expected decline in Covid-19-related demand. Other strategic growth engines, namely new Healthcare products and our Semiconductor Solutions business unit, also performed well in fiscal 2022."
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com